Pain in Patients With Crohn Disease (PAINCD)
Märksõnad
Abstraktne
Kirjeldus
Abdominal pain is a common symptom in patients with inflammatory bowel disease (IBD) that alters quality of life and can lead to increased healthcare utilization. In addition to abdominal pain, pain can result from extra-intestinal manifestation of IBD. 40% of IBD patients suffer from extra-intestinal manifestations. Although abdominal pain has been traditionally attributed to inflammation, functional abdominal pain exists in patients with IBD, associated with a variety of potential causes. About 20-40% of patients in complete clinical and endoscopic remission continue to experience chronic pain. Thus, when examining an IBD patient with abdominal pain, in addition to IBD-related complications (e.g., inflammation, stricture), it is important to screen for other contributors, including peripheral factors (visceral hypersensitivity, bacterial overgrowth, and bowel dysmotility) and centrally mediated neurobiological and psychosocial underpinnings. These central factors include psychological symptoms, sleep disturbance, and stress. Opioid-induced hyperalgesia (e.g., narcotic bowel syndrome) is also growing in recognition as a potential central source of abdominal pain.
Pronounced severe pain impacts health related quality of life (QoL). Longstanding pain leads to decreased QoL, increase in pain medication intake, and co-morbidities including depression, anxiety and even addiction. Furthermore, pain attacks severely interfere with social and professional life.
Knowledge of these potential aetiologies should be used to individualize treatment of abdominal pain in patients with IBD. Accurate assessment of the source of pain can help guide appropriate diagnosis workup and use of modifying therapy.
The aim of the study is to determine the epidemiology of pain in patients with Crohn disease (CD) and to characterize their pain (localisation, temporal characteristics, acute vs. chronic, sensorial characteristics, existence of neuropathic component, existence of hyperalgesia), and their impact of QoL, depression and anxiety
Kuupäevad
| Viimati kinnitatud: | 06/30/2020 |
| Esmalt esitatud: | 07/14/2020 |
| Hinnanguline registreerumine on esitatud: | 07/22/2020 |
| Esmalt postitatud: | 07/26/2020 |
| Viimane värskendus on esitatud: | 07/22/2020 |
| Viimati värskendus postitatud: | 07/26/2020 |
| Õppe tegelik alguskuupäev: | 09/30/2020 |
| Eeldatav esmane lõpetamise kuupäev: | 12/31/2020 |
| Eeldatav uuringu lõpetamise kuupäev: | 01/31/2021 |
Seisund või haigus
Faas
Abikõlblikkuse kriteeriumid
| Õppimiseks sobivad vanused | 18 Years To 18 Years |
| Uuringuks kõlblikud sood | All |
| Proovivõtumeetod | Non-Probability Sample |
| Võtab vastu tervislikke vabatahtlikke | Jah |
| Kriteeriumid | Inclusion Criteria: - any patient with Crohn disease in remission or relapse period age ≥ 18 yo. Exclusion Criteria: - No exclusion criteria beside no informed consent and inadequate French language skills |
Tulemus
Esmased tulemusnäitajad
1. Pain intensity in patients with Crohn Disease (CD) [During the last 30 days]
Sekundaarsed tulemusmõõdud
1. Presence of hyperalgesia [During the last 30 days]
2. Search for a neuropathic component of pain [During the last 30 days]
3. Investigation of the impact of pain on depression and anxietey [During the last 30 days]
